This site is intended for healthcare professionals

BrainStorm Cell Therapeutics announces peer reviewed publication of NurOwn's phase III study for ALS in Muscle and Nerve journal.

Read time: 1 mins
Published:28th Dec 2021
BrainStorm Cell Therapeutics Inc. a leading developer of cellular therapies for neurodegenerative diseases, announced the peer reviewed publication of Phase III clinical data in Muscle and Nerve.

The paper is entitled "A Randomized Placebo-Controlled Phase III Study of Mesenchymal Stem Cells Induced to Secrete High Levels of Neurotrophic Factors in Amyotrophic Lateral Sclerosis."

Data from the paper are from a randomized, double-blind, placebo-controlled, Phase III trial evaluating the safety and efficacy of repeat doses of NurOwn (stem cell therapy) in study participants. Although previously announced results showed the trial did not reach statistical significance on the primary or secondary endpoints, pre-specified and post hoc analyses show a NurOwn-induced treatment effect across both primary and secondary efficacy outcomes in those with less advanced disease.

See -

Muscle & Nerve- "A Randomized Placebo-Controlled Phase III Study of Mesenchymal stem cells induced to secrete high levels of neurotrophic factors in Amyotrophic Lateral Sclerosis."- Merit E. Cudkowicz MD, Stacy R. Lindborg PhD, Namita A. Goyal MD, Robert G. Miller MD, Matthew J. Burford MD, James D. Berry MD, Katharine A. Nicholson MD, Tahseen Mozaffar MD … et. al., First published: 10 December 2021

Condition: Amyotrophic Lateral Sclerosis/Lou Gehrig's Diseas
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.